COMMUNIQUÉS West-GlobeNewswire

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
26/03/2026
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
SIGA Declares Special Cash Dividend of $0.60 Per Share
26/03/2026
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0. [...]
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March [...]
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings
26/03/2026
Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders’ [...]
Galapagos Announces Nomination of Gino Santini to its Board of Directors
26/03/2026
Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry leadership [...]
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
26/03/2026
Exo-Top Inc. positioned as a strategic U.S. subsidiary supporting manufacturing, clinical advancement and long-term value creation TORONTO and HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ( [...]
CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported [...]
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
26/03/2026
New Leadership to Accelerate Market Adoption and Scale Commercial Growth GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical [...]
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
26/03/2026
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2025 Financial Results on March 31, 2026
26/03/2026
FREDERICK, Md., March 26, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader [...]
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
26/03/2026
Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25 Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to [...]
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
26/03/2026
Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025 In February, Spero’s licensing partner, [...]
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 [...]
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
26/03/2026
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from [...]
NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES / ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
26/03/2026
Ghent, Belgium, March 26, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION 26 March 2026, 8:00 pm CET Ghent, Belgium, 26 March 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the [...]
Wake Radiology Chief Operating Officer Parul Galloway Receives 2026 Women in Business Award by the Triangle Business Journal
26/03/2026
Recognition Celebrates Ms. Galloway’s Leadership, Mentorship and Painstaking Efforts in Expanding Access to Exceptional Patient Care RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Wake Radiology UNC Health Rex is [...]
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
26/03/2026
Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen’s position in oncology, rare diseases, and medical devices Target CRO operates across 20+ countries, [...]
Valneva participera à plusieurs événements lors du 25ème World Vaccine Congress de Washington
26/03/2026
Lyon (France), le 26 mars 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins a annoncé aujourd'hui sa présence au 26ème World Vaccine Congress, qui se tiendra du 31 mars au 2 [...]

Pages